BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 23818359)

  • 21. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model.
    Cannizzo E; Carulli G; Del Vecchio L; Ottaviano V; Bellio E; Zenari E; Azzarà A; Petrini M; Preffer F
    Am J Clin Pathol; 2012 Mar; 137(3):377-86. PubMed ID: 22338049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma cells composing plasmacytoma have phenotypes different from those of myeloma cells.
    Sakai A; Fujii T; Noda M; Hyodo H; Oda K; Kimura A
    Am J Hematol; 1996 Dec; 53(4):251-3. PubMed ID: 8948665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extranodal marginal zone B cell lymphomas of the uvea: an analysis of 13 cases.
    Coupland SE; Foss HD; Hidayat AA; Cockerham GC; Hummel M; Stein H
    J Pathol; 2002 Jul; 197(3):333-40. PubMed ID: 12115879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
    Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative quantification of residual tumor cells by lightcycler real-time IgH PCR in autografted multiple myeloma patients.
    Rimelen V; Ferrand C; Debecker A; Sovalat H; Tancredi C; Eidenschenk A; Hénon P
    Leukemia; 2005 Mar; 19(3):492-5. PubMed ID: 15625553
    [No Abstract]   [Full Text] [Related]  

  • 26. Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients.
    Sedlarikova L; Kubiczkova L; Kryukov F; Pelcova J; Adam Z; Pour L; Hajek R; Sevcikova S
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):554-61. PubMed ID: 24993743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of minimal residual disease in multiple myeloma patients detected by 8-color panels and next generation flow cytometry].
    Wang XF; Wang TT; Zhang ZY; Zhou HX; Zhang YR; Chen WM; Geng CY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):512-517. PubMed ID: 31340626
    [No Abstract]   [Full Text] [Related]  

  • 28. A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.
    Frébet E; Abraham J; Geneviève F; Lepelley P; Daliphard S; Bardet V; Amsellem S; Guy J; Mullier F; Durrieu F; Venon MD; Leleu X; Jaccard A; Faucher JL; Béné MC; Feuillard J;
    Cytometry B Clin Cytom; 2011 May; 80(3):176-85. PubMed ID: 21520405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.
    Pilarski LM; Seeberger K; Coupland RW; Eshpeter A; Keats JJ; Taylor BJ; Belch AR
    Exp Hematol; 2002 Mar; 30(3):221-8. PubMed ID: 11882359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.
    Martínez-Sánchez P; Montejano L; Sarasquete ME; García-Sanz R; Fernández-Redondo E; Ayala R; Montalbán MA; Martínez R; García Laraña J; Alegre A; Hernández B; Lahuerta JJ; Martínez-López J
    Br J Haematol; 2008 Sep; 142(5):766-74. PubMed ID: 18637804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
    Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
    Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
    Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
    Sarasquete ME; García-Sanz R; González D; Martínez J; Mateo G; Martínez P; Ribera JM; Hernández JM; Lahuerta JJ; Orfão A; González M; San Miguel JF
    Haematologica; 2005 Oct; 90(10):1365-72. PubMed ID: 16219573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells.
    Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Ikemoto T; Tanaka H; Nishimura Y; Tsuji M; Hanafusa T
    Diagn Pathol; 2012 Sep; 7():131. PubMed ID: 23021410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.
    Korthals M; Sehnke N; Kronenwett R; Bruns I; Mau J; Zohren F; Haas R; Kobbe G; Fenk R
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):423-431.e3. PubMed ID: 21745451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
    Kimlinger T; Witzig TE
    Bone Marrow Transplant; 1997 Mar; 19(6):553-6. PubMed ID: 9085734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay.
    Rasmussen T; Poulsen TS; Honoré L; Johnsen HE
    Exp Hematol; 2000 Sep; 28(9):1039-45. PubMed ID: 11008016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
    Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
    Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation.
    Martinelli G; Terragna C; Zamagni E; Ronconi S; Tosi P; Lemoli R; Bandini G; Testoni N; Amabile M; Ottaviani E; Buonamici S; Soverini S; Montefusco V; de Vivo A; Bonifazi F; Tura S; Cavo M
    Haematologica; 2000 Sep; 85(9):930-4. PubMed ID: 10980631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.